Stock Track | Nurix Therapeutics Plummets 5% Intraday on Q4 Losses and Foreign Exchange Risk Concerns

Stock Track01-30

Nurix Therapeutics' stock plummeted 5% during intraday trading on Friday, reflecting heightened investor concerns following recent financial disclosures and risk assessments.

The decline comes after the company reported its fourth-quarter fiscal 2025 results, revealing a basic EPS loss of $0.82 on revenue of $13.6 million. Analysis highlighted ongoing profitability challenges, with trailing twelve-month losses reaching $264.46 million against revenue of $84.0 million, and expectations that the company won't achieve profitability within the next three years. Additionally, the stock trades at a rich 21.5x P/S multiple compared to industry peers, and shareholders have experienced material dilution over the past year.

Further pressure emerged from a separate disclosure indicating significant foreign exchange risk due to unhedged currency exposure, adding another layer of uncertainty for investors already concerned about the company's financial trajectory.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1105395362?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-30 23:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105395362","market":"sg","top_or_hot":-1,"title":"Stock Track | Nurix Therapeutics Plummets 5% Intraday on Q4 Losses and Foreign Exchange Risk Concerns","media":"Stock Track","content":"<p>Nurix Therapeutics' stock plummeted 5% during intraday trading on Friday, reflecting heightened investor concerns following recent financial disclosures and risk assessments.</p><p>The decline comes after the company reported its fourth-quarter fiscal 2025 results, revealing a basic EPS loss of $0.82 on revenue of $13.6 million. Analysis highlighted ongoing profitability challenges, with trailing twelve-month losses reaching $264.46 million against revenue of $84.0 million, and expectations that the company won't achieve profitability within the next three years. Additionally, the stock trades at a rich 21.5x P/S multiple compared to industry peers, and shareholders have experienced material dilution over the past year.</p><p>Further pressure emerged from a separate disclosure indicating significant foreign exchange risk due to unhedged currency exposure, adding another layer of uncertainty for investors already concerned about the company's financial trajectory.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Nurix Therapeutics Plummets 5% Intraday on Q4 Losses and Foreign Exchange Risk Concerns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Nurix Therapeutics Plummets 5% Intraday on Q4 Losses and Foreign Exchange Risk Concerns\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-01-30 23:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Nurix Therapeutics' stock plummeted 5% during intraday trading on Friday, reflecting heightened investor concerns following recent financial disclosures and risk assessments.</p><p>The decline comes after the company reported its fourth-quarter fiscal 2025 results, revealing a basic EPS loss of $0.82 on revenue of $13.6 million. Analysis highlighted ongoing profitability challenges, with trailing twelve-month losses reaching $264.46 million against revenue of $84.0 million, and expectations that the company won't achieve profitability within the next three years. Additionally, the stock trades at a rich 21.5x P/S multiple compared to industry peers, and shareholders have experienced material dilution over the past year.</p><p>Further pressure emerged from a separate disclosure indicating significant foreign exchange risk due to unhedged currency exposure, adding another layer of uncertainty for investors already concerned about the company's financial trajectory.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NRIX","symbol_name":"Nurix Therapeutics","start_time":0,"source_url":"","article_id":"1105395362","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105395362","pubTimestamp":1769786683,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Nurix Therapeutics' stock plummeted 5% during intraday trading on Friday, reflecting heightened investor concerns following recent financial disclosures and risk assessments.The decline comes after...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NRIX":"Nurix Therapeutics"},"translate_title":"个股追踪|Nurix Therapeutics盘中暴跌5%受Q4亏损及外汇风险担忧影响","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRIX":1},"content_text":"Nurix Therapeutics' stock plummeted 5% during intraday trading on Friday, reflecting heightened investor concerns following recent financial disclosures and risk assessments.The decline comes after the company reported its fourth-quarter fiscal 2025 results, revealing a basic EPS loss of $0.82 on revenue of $13.6 million. Analysis highlighted ongoing profitability challenges, with trailing twelve-month losses reaching $264.46 million against revenue of $84.0 million, and expectations that the company won't achieve profitability within the next three years. Additionally, the stock trades at a rich 21.5x P/S multiple compared to industry peers, and shareholders have experienced material dilution over the past year.Further pressure emerged from a separate disclosure indicating significant foreign exchange risk due to unhedged currency exposure, adding another layer of uncertainty for investors already concerned about the company's financial trajectory.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1105395362","isCrawlerRequest":true}